These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7854356)

  • 1. Antiestrogens increase protein tyrosine phosphatase activity in human breast cancer cells.
    Freiss G; Vignon F
    Mol Endocrinol; 1994 Oct; 8(10):1389-96. PubMed ID: 7854356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extinction of insulin-like growth factor-I mitogenic signaling by antiestrogen-stimulated Fas-associated protein tyrosine phosphatase-1 in human breast cancer cells.
    Freiss G; Puech C; Vignon F
    Mol Endocrinol; 1998 Apr; 12(4):568-79. PubMed ID: 9544992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell cycle phase dependence of estrogen and epidermal growth factor (EGF) receptor expression in MCF-7 cells: implications in antiestrogen and EGF cell responsiveness.
    Dong XF; Berthois Y; Colomb E; Martin PM
    Endocrinology; 1991 Nov; 129(5):2719-28. PubMed ID: 1935801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of two estrogen-responsive proteins by antiestrogens in R27, a tamoxifen-resistant clone of MCF7 cells.
    Vignon F; Lippman ME; Nawata H; Derocq D; Rochefort H
    Cancer Res; 1984 May; 44(5):2084-8. PubMed ID: 6713400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of estrogen and antiestrogen on transforming growth factor gene expression in endometrial adenocarcinoma cells.
    Gong Y; Ballejo G; Murphy LC; Murphy LJ
    Cancer Res; 1992 Apr; 52(7):1704-9. PubMed ID: 1551100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog.
    Catherino WH; Wolf DM; Jordan VC
    Mol Endocrinol; 1995 Aug; 9(8):1053-63. PubMed ID: 7476979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation.
    Jeng MH; Parker CJ; Jordan VC
    Cancer Res; 1992 Dec; 52(23):6539-46. PubMed ID: 1423300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of 4-hydroxytamoxifen anti-growth factor activity in breast cancer cells: alterations of growth factor receptor binding sites and tyrosine kinase activity.
    Freiss G; Rochefort H; Vignon F
    Biochem Biophys Res Commun; 1990 Dec; 173(3):919-26. PubMed ID: 2268352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiestrogens prevent the stimulatory effects of L-triiodothyronine on cell proliferation.
    Zhou-Li F; Albaladejo V; Joly-Pharaboz MO; Nicolas B; Andre J
    Endocrinology; 1992 Mar; 130(3):1145-52. PubMed ID: 1537281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of intracellular Ca2+ in the epidermal growth factor induced inhibition of protein tyrosine phosphatase activity in a breast cancer cell line.
    Mishra S; Hamburger AW
    Biochem Biophys Res Commun; 1993 Mar; 191(3):1066-72. PubMed ID: 7682060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth.
    Coezy E; Borgna JL; Rochefort H
    Cancer Res; 1982 Jan; 42(1):317-23. PubMed ID: 7053859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase.
    Gründker C; Völker P; Emons G
    Endocrinology; 2001 Jun; 142(6):2369-80. PubMed ID: 11356684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbeta1.
    Liang Y; Hou M; Kallab AM; Barrett JT; El Etreby F; Schoenlein PV
    Int J Oncol; 2003 Aug; 23(2):369-80. PubMed ID: 12851686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of the growth-inhibitory effects of progestins and the antiestrogen hydroxyclomiphene on human breast cancer cells by epidermal growth factor and insulin.
    Koga M; Musgrove EA; Sutherland RL
    Cancer Res; 1989 Jan; 49(1):112-6. PubMed ID: 2642286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines.
    Müller V; Jensen EV; Knabbe C
    Cancer Res; 1998 Jan; 58(2):263-7. PubMed ID: 9443403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic antiestrogens modulate induction of pS2 and cathepsin-D messenger ribonucleic acid by growth factors and adenosine 3',5'-monophosphate in MCF7 cells.
    Chalbos D; Philips A; Galtier F; Rochefort H
    Endocrinology; 1993 Aug; 133(2):571-6. PubMed ID: 8344199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor-mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen.
    Taylor CM; Blanchard B; Zava DT
    Cancer Res; 1984 Apr; 44(4):1409-14. PubMed ID: 6704959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of tumor necrosis factor-alpha on the phosphorylation of tyrosine kinase receptors is associated with dynamic alterations in specific protein-tyrosine phosphatases.
    Ahmad F; Goldstein BJ
    J Cell Biochem; 1997 Jan; 64(1):117-27. PubMed ID: 9015760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells.
    Poulin R; Merand Y; Poirier D; Levesque C; Dufour JM; Labrie F
    Breast Cancer Res Treat; 1989 Oct; 14(1):65-76. PubMed ID: 2605344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.